Betrixaban
BEVYXXA
Pronunciation: be-TRIX-a-ban
What it isOral direct factor Xa inhibitor (DOAC) with a long half-life and minimal CYP metabolism, largely eliminated unchanged and dependent on P-glycoprotein.
Why this oneIt was approved uniquely for extended VTE prophylaxis in acutely ill hospitalized medical patients, a longer-duration indication other DOACs lacked (now discontinued in the US).
What limits itCarries a boxed warning for spinal/epidural hematoma with neuraxial procedures, interacts via P-gp, and requires dose reduction or avoidance in renal impairment.
Betrixaban prescription history
Animated chart of estimated U.S. prescriptions per year, Antithrombotics (1914–2026). Betrixaban enters in 2017 (estimated).
⚠ BOXED WARNING
- spinal/epidural hematoma
Principal riskEpidural or spinal hematoma, which can cause long-term or permanent paralysis, may occur in patients receiving neuraxial anesthesia or undergoing spinal puncture.
Classes and tags
Clinical profile
Open Betrixaban in the interactive console ↗
Self-check
- Which transporter governs betrixaban interactions?
P-glycoprotein. - What boxed procedural risk applies to betrixaban?
Spinal/epidural hematoma with neuraxial procedures.